Risperidone Long-Acting Injection Suppliers & Bulk Manufacturers

Available Forms: Long-Acting Injection

Available Strengths: 12.5 mg, 25 mg, 37.5 mg, 50 mg vials/syringes

Reference Brands: Risperdal Consta(US &EU)

Category: Antipsychotropic Drugs

Risperidone Long-Acting Injection is available in Long-Acting Injection and strengths such as 12.5 mg, 25 mg, 37.5 mg, 50 mg vials/syringes. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Risperidone Long-Acting Injection is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Risperidone Long-Acting Injection can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description: Risperidone Long-Acting Injection, commonly marketed as Risperdal Consta, is a second-generation antipsychotic approved in both the US (FDA) and EU (EMA) for the treatment of schizophrenia and maintenance therapy in bipolar disorder. It is administered intramuscularly every two weeks and provides steady plasma levels, improving adherence in patients with chronic psychosis. The drug requires prior oral risperidone trial before initiating long-acting therapy. In the EU, it is approved under centralized and national procedures. In the US, it holds FDA approval under NDA. Its prolonged-release formulation is protected by a series of patents, though generic development has begun in select markets.